Suppressed antithrombin III activity and unregulated thrombin activity have broadly been reported in the plasma of patients with lung adenocarcinomas, renal cell carcinomas, breast cancer, malignant melanomas, colon cancer, pancreatic adenocarcinomas, and larynx squamous cell carcinomas [13-16]. Here, SERPINC1 is linked to laryngeal squamous cell carcinoma.